Inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene underlies the majority of sporadic clear cell renal cell carcinomas (CCRCCs) and is also responsible for the hereditary VHL cancer syndrome. VHL loss of function results in constitutive stabilization of hypoxia-inducible factors (HIF-1a and HIF-2a) due to insufficient proteolysis in the presence of oxygen. This activates multiple genes relevant to tumorigenesis, allowing cells to acquire further mutations and undergo malignant transformation. However, the specific role of each HIF-a subunit in CCRCC tumorigenesis is not yet well understood. The current paradigm supports that in the first stages of CCRCC formation the stabilization of HIF-1a is dominant and this limits proliferation, but later on HIF-2a increases and this induces a more aggressive cell behavior. Understanding how this transition happens is highly relevant, as it may provide novel ways to treat these cancers. Here, we show that VHL inactivation in CCRCC cells results in HIF-1a/2a-dependent downregulation of HIF-1a mRNA through direct binding of either subunit to a reverse hypoxia-response element in the HIF-1a proximal promoter. This binding activates a series of repressive histone modification marks including histone 3 lysine 27 trimethylation (H3K27me3) to make the changes stable, and if overturned reduces CCRCC cell proliferation due to excessive HIF-1a expression level. Our findings thus help understand how HIF-a subunits influence each other and also reinforce the idea that epigenetic mechanisms are a key step of CCRCC progression.
Introduction
Poor oxygenation (hypoxia) is a common feature of solid tumors, resulting from the compromise between oxygen delivery by the vasculature and quick tumor growth, and is often associated with increased malignancy, resistance to therapy and poor prognosis (Semenza, 2003) . Cells respond to hypoxia by initiating changes in gene expression that promote adaptation. The hypoxia-inducible factor (HIF) signaling pathway is a master regulator of this (Semenza, 2001; Pugh and Ratcliffe, 2003) , although other mechanisms are also involved. HIF is a heterodimeric transcription factor composed of a-and b-subunits; the level of oxygenation regulates the stability of a-subunits, whereas b-subunits are constitutively expressed. In the presence of adequate oxygenation, a family of oxygen-dependent dioxygenases termed PHDs (prolyl hydroxylase domaincontaining proteins) catalyzes the hydroxylation of key proline residues in the central part of HIF-a subunits (Schofield and Ratcliffe, 2004) . von Hippel-Lindau (VHL) protein (pVHL) acts as the recognition component of a complex with E3-ubiquitin ligase activity that binds hydroxylated HIF-a subunits and promotes their efficient degradation by the proteasome (Maxwell et al., 1999) . It comprises two isoforms, pVHL19 and 30, which arise from alternative transcription initiation sites but share the ability to regulate HIF-a (Kaelin, 2002) . In the absence of oxygen, HIF-a subunits are not hydroxylated by the PHDs, consequently escape recognition by pVHL and become stabilized, and then translocate to the nucleus to bind HIF-1b and activate gene transcription through specific DNA sequences termed hypoxiaresponse elements (HREs; Wenger et al., 2005) . This influences the expression of numerous genes affecting almost any aspect of cell function/human physiology, such as angiogenesis, metabolism, cell proliferation and death (Semenza, 2003) . There are three HIF-a isoforms, HIF-1a, HIF-2a and HIF-3a; the first two have been more studied (Kaelin, 2008) . The function of HIF-1a and HIF-2a is shared in some cases, as indeed both transcription factors bind to similar DNA sequences (Wenger et al., 2005) . However, some genes are more effectively regulated by either one transcription factor or the other, suggesting that mechanisms exist that ensure specificity (Dayan et al., 2006; Esteban et al., 2006b; Roberts et al., 2009) .
VHL loss of function happens in the majority of clear cell renal cell carcinomas (CCRCCs), which represent the most frequent form of renal cancer (Kaelin, 2002) . VHL-defective CCRCC cells display constitutive HIF-a stabilization under normal oxygenation and this is responsible for tumor formation (Kaelin, 2002) . VHL is also inactivated in the VHL syndrome; an autosomal dominant syndrome characterized by cysts (especially in the kidney), and a variety of tumors (in particular CCRCC). According to Knudson's two-hit model of cancer, CCRCC in VHL disease only develops after mutation or inactivation (for example, DNA methylation) of the remaining wild-type allele. Interestingly, the kidneys from patients with VHL disease contain multiple lesions of early biallelic VHL inactivation that develop before noticeable tumors appear (Mandriota et al., 2002) . These early lesions are located inside otherwise normal kidney tubules and in most cases never progress, presumably because of apoptosis. The lesions display more potent activation of HIF-1a than HIF-2a, but such balance is shifted latter on to allow tumor progression (Mandriota et al., 2002) . In the early stages of CCRCC development, HIF-1a likely confers a metabolic advantage, for example, by inducing genes related to anaerobic glycolysis (Semenza, 2003) . However, the evolution to a more advanced stage is slow or inexistent, perhaps related to the fact that HIF-1a can induce cell cycle arrest or apoptosis (Semenza, 2003; Koshiji et al., 2004) . In this regard, it is believed that only when HIF-2a becomes dominant, then CCRCC cells escape HIF-1a-negative effects and the tumor progresses (Gordan et al., 2008) . How such transition happens is unknown but likely involves multiple mechanisms, as in some cases the phenomenon is so extreme that some CCRCC cell lines in vitro or tumor samples from patients express HIF-2a but lack detectable HIF-1a (Maxwell et al., 1999) . Notably, overexpression or suppression of HIF-a or HIF-2a has been shown to reciprocally influence each other at the protein level in vitro (Raval et al., 2005) , which may provide an explanation for the changes observed in vivo. Understanding this phenomenon is highly relevant, as it may provide a basis for novel therapeutic interventions. In this report, we aimed to shed light into this issue in the context of VHL-defective CCRCC cells. et al. (2005) have demonstrated previously that HIF-1a/2a subunits influence each other in VHLdefective CCRCC cells. Specifically, they showed that small interfering RNA (siRNA) for HIF-1a increases HIF-2a protein, whereas overexpression or siRNA for HIF-2a reduces and increases HIF-1a protein, respectively. This dual effect has been reproduced by others using unrelated cell types (Menrad et al., 2010) , but the underlying mechanisms remain elusive. Raval et al. (2005) demonstrated that the effect of HIF-2a on HIF1a protein requires HIF-2a binding to DNA, but concluded that it is indirect and likely involves reduced HIF-1a protein translation. On the other hand, Menrad et al. (2010) suggested that free radicals generated upon HIF-2a siRNA knockdown mediate HIF-1a induction in hepatocarcinoma cells. The increase in free radicals would be explained by a decrease in antioxidant enzymes (for example, catalase) that are normally activated by HIF-2a. In our study, we hypothesized that the stabilization of HIF-1a/2a subunits in VHLdefective CCRCC cells may limit HIF-1a expression by direct binding to specific sequences in the HIF-1a promoter.
Results and discussion

Raval
First, we overexpressed a constitutively stable form of HIF-2a (HIF-2a DM) in VHL-defective CCRCC cell lines (RCC10 and RCC4; Xu et al., 2010) . Western blotting confirmed the repression of HIF-1a protein by HIF-2a in the two cell lines (Figure 1a ), in agreement with the data by Raval et al. (2005) . But in contrast to this report, we observed reduction of HIF-1a mRNA by quantitative PCR (qPCR) analysis of three independent experiments (Figure 1b ), although this reduction was more moderate in RCC4 (down to B60%) than in RCC10 (down to B30%) cells. A plausible explanation for the discrepancy could be that the authors mainly focused their study on VHL-defective RCC4 cells (Raval et al., 2005) . Overexpression of a constitutively stable HIF-1a (HIF-1a DM) could as well reduce endogenous HIF-1a mRNA in VHL-defective RCC10 and RCC4 cells ( Figure 1b) . As expected, HIF-1a DM and HIF-2a DM induced vascular endothelial growth factor (VEGF) mRNA, whereas endogenous HIF-2a mRNA remained unaffected ( Figure 1b) . We then transfected VHLdefective RCC10 and RCC4 cells with two independent sets of siRNA oligos for HIF-2a. Western blot showed increase of HIF-1a protein upon HIF-2a knockdown in the two cell types (Figure 1c) , and this had a match at the mRNA level as assessed by qPCR ( Figure 1d) . A HIF-1a-specific target gene, Bcl-2/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3; Kothari et al., 2003) , was likewise increased at the protein and mRNA levels upon HIF-2a knockdown (Figures 1c and d) . Therefore, stabilized HIF-1a/2a subunits reduce HIF-1a mRNA in VHL-defective CCRCC cells.
Next, we tested whether VHL re-expression into otherwise defective CCRCC cells increases HIF-1a mRNA by suppressing the constitutive stabilization of HIF-1a and HIF-2a proteins. We generated pools of VHL-defective RCC10 and RCC4 cells infected with retroviral vectors that produce the longer pVHL isoform (pVHL30) or the empty vector. Suppression of HIF-1a and HIF-2a proteins by pVHL30 was verified by western blotting (Figure 2a) . Notably, HIF-1a mRNA was potently increased by pVHL30 in both CCRCC genetic backgrounds, whereas HIF-2a mRNA remained unchanged ( Figure 2b ). To further demonstrate that VHL re-expression is acting via suppression of HIF-1a/2a, we overexpressed HIF-1a DM or HIF-2a DM in VHL-expressing RCC10 and RCC4 cells, which reduced endogenous HIF-1a mRNA more potently than in their VHL-defective counterparts ( Figure 2c ). We also studied the effect of the VHL status on HIF-1a mRNA using surgical samples from sporadic VHL-defective CCRCC tumors and paired normal tissue obtained during the same nephrectomies. HIF-1a mRNA was reduced in the tumors compared with the normal tissues and HIF-2a DM (prolines 405 and 531) or green fluorescent protein (control) were prepared using a lentiviral backbone vector developed in our lab. Viral supernatants were produced in HEK293T cells after co-transfection with packaging lentiviral vectors pMD2.G and psPAX2. Only one round of infection (duration 24 h) was applied. All cell types used in this study were cultured in RPMI1640 (Gibco, Carlsbad, CA, USA) with 10% fetal bovine serum (Gibco). Lysates were obtained using RIPA buffer. Rabbit polyclonal anti-HIF-1a and anti-HIF-2a were purchased from BD Biosciences (Franklin Lakes, NJ, USA) and Novus Biologicals (Littleton, CO, USA), respectively, and mouse monoclonal anti-tubulin from Sigma (St Louis, MO, USA). Western blotting was performed using ECL Plus (Amersham, Uppsala, Sweden). (b) qPCR for the indicated targets in the same VHL-defective RCC10 and RCC4 pools; mean values of three independent experiments and the s.d. are shown (this applies hereafter to all data containing error bars). *P-value o0.05 as analyzed by Student's t-test. qPCR was performed using SYBR Green (Takara, Shiga, Japan) and an ABI7300 machine (Life Technologies, Carlsbad, CA, USA). Samples were measured in triplicate and normalized on the basis of b-actin values. All primer sequences used in this study (also the target sequences for the siRNA oligos) are listed in Supplementary Table S1 . (c) Representative western blot with the indicated antibodies and lysates from VHL-defective RCC10 and RCC4 cells transfected with siRNA (si) oligos for HIF-2a (50 nM, also hereafter). Cells were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) following the instructions by the manufacturer. Transfected cells were split onto the appropriate surfaces after 24 h and lysed after an additional 4 days. siRNA oligos for the firefly luciferase gene were used as control (Ctrl; also hereafter). These siRNA oligos have been described before (Xu et al., 2010) and were purchased from Guangzhou Ribobio (Guaugdong, PR China) (other siRNAs described hereafter too). BNIP3 antibodies were purchased from Abcam (Cambridge, MA, USA). (d) qPCR analysis for the indicated targets with samples from three independent siRNA transfection experiments. RNA samples were also extracted at day 4 after splitting.
( Figure 2d ), and we observed that HIF-2a mRNA displayed the opposite behavior. Therefore, VHL re-expression in CCRCC cells increases HIF-1a mRNA, whereas overexpression of HIF-1a/2a subunits in VHLexpressing CCRCC cells reverses this. Moreover, VHLdependent regulation of HIF-1a mRNA can be observed as well in CCRCC in vivo.
We searched the HIF-1a proximal promoter (1 kb upstream from the translation initiation site ATG) for putative HREs and found multiple candidate sequences, both conventional and unconventional (reverse HREs: conventional sequence on the minus DNA strand; Figure 3a ). The latter sequences are hereafter referred to as rHREs. Of note, binding of HIF-a subunits to rHREs has been described as a mechanism to repress transcription in hypoxia (Narravula and Colgan, 2001; Mazure et al., 2002; Jeong et al., 2007; Lee et al., 2010) . We cloned this entire HIF-1a promoter fragment (HIF1APro) upstream of the firefly luciferase gene and transfected the reporter plasmid into HEK293T cells together with HIF-1a DM and HIF-2a DM or control empty vector (Figure 3b) . We prepared as well a shorter version of only 252 bp (HIF1ProT) containing a single rHRE ( Figure 3a) ; a luciferase reporter plasmid containing a part of the vascular endothelial growth factor promoter was used as control. This rHRE is separated from a recently reported conventional HRE whose DNA methylation status determines HIF-1a accessibility and positive self-regulation (Koslowski et al., 2011) ( Supplementary Figures S1a and b) . Both HIF-1a DM and HIF-2a DM repressed the longer and shorter HIF-1a promoters, suggesting that the key regulatory element for this effect lies in the shorter fragment ( Figure 3b) ; VEGF reporter activity was enhanced. Notably, mutation of the rHRE sequence in the shorter promoter (HIF1AProTM) completely abolished the repression by both HIF-a subunits (Figure 3b) . We also studied the activity of the longer and shorter HIF-1a promoter fragments in VHL-defective RCC4 cells transfected with siRNA for HIF-1a and HIF-2a. We observed that siRNA for HIF-1a/2a increased the activity of the longer and shorter promoters compared with control siRNA, but had no effect on the shorter fragment that bears a mutated rHRE (Figure 3c ). We Table S1 ). Mean values of three independent experiments are shown. HIF-1a/2a overexpression was verified by western blotting (data not shown). (d) qPCR for the indicated genes using samples from eight sporadic VHL-defective CCRCC tumors obtained by nephrectomy. Values are referred to the corresponding paired normal tissue surrounding the tumor. PHD3 analysis was used to demonstrate constitutive activation of the HIF pathway in the tumors. **P-value o0.01 and ***P-value o0.001. (a) Schematic representation of different fragments of the HIF-1a proximal promoter. The þ 1 position is counted from the translation initiation site. Putative rHRE sequences are represented as empty boxes. HIF1APro stands for the longer promoter fragment, HIF1AProT for the shorter and HIF1AProTM for the shorter fragment containing an rHRE mutated using site-directed mutagenesis (performed using PCRbased method and verified by sequencing). *P-valueo0.05. (b) Activity of the same promoter constructs cloned upstream of the luciferase gene in pGL3Basic vector and cotransfected into HEK293T cells together with empty pcDNA3 vector, HIF1a-DM or HIF2a-DM. The control plasmid used was 9 Â VEGF HRE, which contains 9 copies of the HRE in the vascular endothelial growth factor promoter (Aragones et al., 2001) . Renilla SV40 plasmid was also cotransfected and used for normalization. A Dual-Glo luciferase assay system (Promega, Madison, WI, USA) and a Veritas Microplate Luminometer (Promega) were used for the detection. (c) Similar experiment in VHL-defective RCC4 cells transfected with siRNA oligos for HIF-1a/2a. siRNA oligos for HIF-1a have been also described before (Xu et al., 2010) . Plasmids were transfected using Fugene (Roche, Upper Bavaria, Germany) using a ratio DNA:Fugene 1:4 following the instructions by the manufacturer. (d) Semiquantitative reverse transcriptase-PCR of chromatin immunoprecipitation (ChIP) samples from VHL-defective RCC10 cells obtained using anti-HIF-1a (Abcam), anti-HIF-2a (Abcam) or IgG control antibodies (Millipore, Billerica, MA, USA). Diluted chromatin (1:10) was used for the input (also in f-h). We followed the X-ChIP protocol from Abcam. Ctrl stands for an unrelated region upstream of the rHRE. Primers for the negative control, the rHRE and PHD3 (Pescador et al., 2005) are listed in Supplementary Table S1 . (e) Electrophoretic mobility shift assay (EMSA) was performed using Chemiluminescent EMSA Kit (Beyotime, Jiangsu, PR China). (f, g) qPCR of ChIP samples from VHL-defective RCC4 or RCC10 cells obtained using anti-H3K9me3, anti-H3K27me3, anti-H3K4me3 or control antibodies (all from Abcam). We followed the N-ChIP protocol from Abcam. Primers are listed in Supplementary Table S1 and a schematic representation of the amplified regions in Supplementary Figure S1c. (h) Similar experiment using VHL-defective RCC10 cells infected with the indicated short hairpin RNA (shRNA) retroviruses. shRNA oligos targeting HIF-a subunits were synthesized and cloned into pSUPER-retro vector (Oligoengine, Seattle, WA, USA). RCC10 cells were infected with these retroviruses and selected with 2 mg/ml puromycin for 4 days. demonstrated specific binding of HIF-1a/2a to this DNA sequence by chromatin immunoprecipitation (ChIP) (followed by semiquantitative reverse transcriptase-PCR; Figure 3d ) and electrophoretic mobility shift assay (EMSA) ( Figure 3e) ; both experiments were performed using VHL-defective RCC10 cells. A known conventional HRE in the PHD3 promoter (Pescador et al., 2005) was used as positive control for the ChIP, and an unrelated region in the HIF-1a promoter as the negative control (Figure 3d and Supplementary Figure   S1a) . A mutated rHRE sequence was used as a control in the EMSA and showed no binding (Figure 3e ).
Histones are proteins that package and organize DNA into structural units termed nucleosomes. They undergo a series of covalent modifications (including methylation) that influence how tightly the DNA is wrapped around them, thus determining transcription factor accessibility (Christophersen and Helin, 2010) . We performed ChIP (followed by qPCR) for the following histone modification marks: histone 3 lysine 9 trimethylation (H3K9me3) and histone 3 lysine 27 trimethylation (H3K27me3), which are associated with transcriptional repression, plus histone 3 lysine 4 trimethylation (H3K4me3), which is associated with transcriptional activation (Christophersen and Helin, 2010) . The position of primers used for qPCR analysis of the ChIP samples is indicated in Supplementary  Figure S1c . H3K27me3 and H3K9me3 were reduced in VHL-defective RCC4 cells infected with a vector producing pVHL30 compared with the control as assessed by qPCR, whereas H3K4me3 was increased (Figure 3f) . Similar results were obtained in VHLdefective RCC10 cells (Figure 3g) , except that the increase in H3K4me3 was more modest. We also observed that infection of VHL-defective RCC10 cells with retroviral vectors producing short hairpin RNA for HIF-1a and HIF-2a had the same effect as pVHL30 on these histone modification marks (Figure 3h and Supplementary Figure S1d ). How these modifications occur will require additional study, but it is tempting to speculate that they involve recruitment of polycomb complex components to HIF-1a/2a-rHRE complexes, as these proteins are responsible for inducing histone methylation in other settings (Schuettengruber et al., 2007) .
Finally, because unbalanced stabilization of HIF-1a is regarded as a mechanism slowing growth in CCRCC (Raval et al., 2005) , we studied whether siRNA knockdown of HIF-2a in VHL-defective CCRCC cells (Supplementary Figure S2 ) could reduce cell proliferation by releasing HIF-1a inhibition. Indeed, we observed that siRNA oligos for HIF-2a effectively reduced VHLdefective RCC10 and RCC4 cell proliferation, and this was partly prevented by concomitant knockdown of HIF1a (Figure 4a ). Apoptosis was likewise increased in VHLdefective CCRCC cells treated with siRNA for HIF-2a, but the effect was modest (Figure 4b ) and there was no synergy upon treatment with tumor necrosis factor-a, Fas (TNF receptor superfamily, member 6) ligand or cisplatin (data not shown). The effect of siRNA for HIF-2a on apoptosis could be alleviated by co-transfection of HIF1a siRNA (Figure 4b ). BNIP3 belongs to the Bcl-2 family of proteins (Cory and Adams, 2002) , which are essential regulators of programmed cell death, and is thought to have a dual role in cell survival, on one side promoting apoptosis (Guo et al., 2001 ) and on the other inducing viability through autophagy (Bellot et al., 2009) . Cotransfection of BNIP3 siRNA reduced the enhanced apoptosis detected upon HIF-2a knockdown in VHLdefective RCC10 and RCC4 cells (Supplementary Figure  S3) , but did not overcome the proliferation reduction (data not shown). Therefore, suppression of HIF-1a protein by HIF-2a in VHL-defective CCRCC cells confers a selective advantage by antagonizing the growth suppressive effect of HIF-1a.
In summary, here we have described that binding of HIF-1a/2a subunits to the HIF-1a promoter creates an auto-regulatory loop in VHL-defective CCRCC cells that helps change the balance of HIF-a subunits toward HIF-2a dominance (Figure 4c ). The alteration of the HIF-1a/2a balance increases CCRCC cell proliferation in vitro and may contribute to the aggressive behavior in vivo. This effect is mediated through direct binding of HIF-a subunits to an rHRE in the HIF-1a proximal promoter. There is no reason to think that a similar mechanism does not operate in other cell types exposed to hypoxia or oncogenic signaling (Menrad et al., 2010) . Supporting this, activation of HIF-1a/2a signaling in skin fibroblasts and renal proximal tubular epithelial cells by the iron chelator desferrioxamine and the 2-oxoglutarate analog dimethyloxalylglycine reduced HIF-1a mRNA effectively (Supplementary Figure S4) . Moreover, a recent report showed reduced HIF-1a mRNA upon exposure of neuroblastoma cells to hypoxia (Lin et al., 2011) . Our data and the recent report by Koslowski et al. (2011) also highlight the importance of epigenetic modifications for controlling HIF-1a expression. In this regard, our model may be applicable as well to other genes repressed by HIF-1a/2a in VHL-defective CCRCC cells or VHL-expressing cells exposed to hypoxia. In fact, accumulation of epigenetic modifications is nowadays emerging as a key mechanism regulating CCRCC tumor formation and hypoxia signaling (Beyer et al., 2008; Pollard et al., 2008; Dalgliesh et al., 2010; Morris et al., 2011; Varela et al., 2011) , and this holds hope for finding new ways to control CCRCC progression through pharmacological manipulation (Yoo and Jones, 2006) .
